吉西他滨与吡柔比星对非肌层浸润性膀胱癌切除术后膀胱灌注不良反应与复发的差异性研究  

Difference between gemcitabine and pirarubicin in the treatment of bladder perfusion adverse reactions and recurrence after resection of non-muscular invasive bladder cancer

作　　者：兰东 黄国华[1] 蓝建华[1] 唐贤富[1] Lan Dong;Huang Guohua;Lan Jianhua;Tang Xianfu(Department of Urology,Guang'an People's Hospital,Sichuan,Guang'an 638500,China)

机构地区：[1]广安市人民医院泌尿外科,四川广安638500

出　　处：《中国医学前沿杂志（电子版）》2021年第10期67-70,共4页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

基　　金：2019年四川省医学(青年创新)科研课题(S19017)。

摘　　要：目的探讨吉西他滨与吡柔比星对非肌层浸润性膀胱癌切除术后膀胱灌注不良反应与复发的差异性。方法选取2017年3月至2019年10月于广安市人民医院诊断并行经尿道膀胱肿瘤切除术的非肌层浸润性膀胱癌患者76例为研究对象,采用随机数字表法将入选患者分为观察组(42例)与对照组(34例),观察组患者术后即刻予以吉西他滨膀胱灌注治疗,对照组术后即刻予以吡柔比星膀胱灌注治疗。比较两组患者3个月、6个月、12个月复发情况、生活质量评分、免疫指标及不良反应发生情况。结果观察组患者治疗后总复发率、CD8^(+)T细胞水平、总不良反应发生率均显著低于对照组(均P<0.05),生活质量评分、免疫球蛋白M、免疫球蛋白G、免疫球蛋白A、C3、C4、CD4^(+)T细胞水平和CD4^(+)T细胞/CD8^(+)T细胞均显著高于对照组(均P<0.05)。结论吉西他滨与吡柔比星对非肌层浸润性膀胱癌患者经尿道膀胱肿瘤切除术后均有一定疗效,但吉西他滨膀胱灌注治疗复发率较低,患者生活质量较高,免疫指标改善显著。Objective To investigate the difference between gemcitabine and pirarubicin in the treatment of bladder perfusion adverse reactions and recurrence after resection of non-muscular invasive bladder cancer.Method A total of 76 patients with nonmuscular invasive bladder cancer diagnosed in Guang'an People's Hospital and treated by transurethral resection of bladder tumor from March 2017 to October 2019 were selected as the research subjects,according to the random number table method,patients were divided into observation group(42 cases)and control group(34 cases),observation group patients showed immediate to gemcitabine bladder perfusion treatment,control group patients received pirobicin bladder infusion immediately after operation.The recurrence,quality of life score,immune indexes and the incidence of adverse reactions were compared between the two groups at 3,6 and 12 months.Result The total recurrence rate,CD8^(+)T cell level,and total incidence of adverse reactions in observation group were significantly lower than those in control group(all P<0.05),the quality of life score,immunoglobulin M,immunoglobulin G,immunoglobulin A,C3,C4,and CD4^(+)T cell levels,and CD4^(+)T cell/CD8^(+)T cell in observation group were significantly higher than those in the control group(all P<0.05).Conclusion Gemcitabine and pirarubicin both showed certain efficacy in patients with invasive bladder cancer after transurethral resection of bladder tumor,but gemcitabine bladder perfusion therapy has a lower recurrence rate,higher quality of life,and significantly improved immune indexes.

关 键 词：吉西他滨 吡柔比星 非肌层浸润性膀胱癌 经尿道膀胱肿瘤切除术 复发 不良反应 

分 类 号：R737.14[医药卫生—肿瘤]